https://oncoinvent.dev2.superwp.no/press-release/ 2026-06-18T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-first-quarter-2017-results-presentation-and-webcast/ 2017-05-16T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/abstract-showing-activity-in-mds-of-bergenbios-first-in-class-axl-inhibitor-bgb324-accepted-for-presentation-at-asco-annual-meeting-2017/ 2017-05-19T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-announces-start-of-randomised-phase-i-ii-trial-assessing-selective-axl-inhibitor-bgb324-in-combination-with-current-therapies-in-melanoma/ 2017-05-22T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-first-quarter-2017/ 2017-05-23T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbios-selective-first-in-class-axl-inhibitor-bgb324-featured-in-a-poster-presentation-at-asco-annual-meeting-2017/ 2017-06-06T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-awarded-nok-24m-from-innovasjon-norge-to-support-the-clinical-development-of-bgb324-in-combination-with-keytruda-for-advanced-lung-cancer/ 2017-06-26T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-exercise-of-employee-share-options-and-increase-of-share-capital/ 2017-06-27T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-registered-2/ 2017-07-13T11:12:17+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-its-first-in-class-selective-axl-inhibitor-bgb324-at-precision-lung-cancer-world-rd-summit-in-boston/ 2017-07-26T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-second-quarter-and-half-year-2017-results-presentation-and-webcast/ 2017-08-11T06:05:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-second-quarter-and-half-year-2017/ 2017-08-18T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bgb324-bergenbios-selective-first-in-class-axl-inhibitor-featured-in-three-clinical-presentations-at-the-18th-world-conference-on-lung-cancer/ 2017-09-28T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/clinical-study-with-bgb324-bergenbios-selective-first-in-class-axl-inhibitor-to-be-presented-at-the-9th-world-congress-of-melanoma/ 2017-10-12T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/klinisk-studie-med-bgb324-bergenbios-selektive-first-in-class-axl-inhibitor-presenteres-pa-9th-world-congress-of-melanoma/ 2017-10-12T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bgb324-bergenbios-selective-first-in-class-axl-inhibitor-featured-in-3-clinical-presentations-at-18th-world-conference-on-lung-cancer-in-yokohama/ 2017-10-16T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/tre-kliniske-studier-med-bgb324-bergenbios-selektive-first-in-class-axl-hemmer-presenteres-pa-den-18ende-verdenskonferansen-om-lungekreft-i-yokohma/ 2017-10-16T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-announces-strong-recruitment-and-encouraging-safety-profile-for-axl-inhibitor-bgb324-in-a-melanoma-study-at-9th-world-congress-of-melanoma/ 2017-10-18T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-announces-strong-recruitment-and-encouraging-safety-profile-for-axl-inhibitor-bgb324-in-a-melanoma-study-at-9th-world-congress-of-melanoma-2/ 2017-10-18T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-announces-start-of-phii-trial-assessing-selective-axl-inhibitor-bgb324-in-combination-with-keytruda-for-patients-with-advanced-breast-cancer/ 2017-10-19T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-announces-start-of-phii-trial-assessing-selective-axl-inhibitor-bgb324-in-combination-with-keytruda-for-patients-with-advanced-breast-cancer-2/ 2017-10-19T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-announces-start-of-ph-ii-trial-assessing-selective-axl-inhibitor-bgb324-in-combination-with-keytruda-for-patients-with-advanced-lung-cancer/ 2017-10-24T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-announces-start-of-ph-ii-trial-assessing-selective-axl-inhibitor-bgb324-in-combination-with-keytruda-for-patients-with-advanced-lung-cancer-2/ 2017-10-24T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/clinical-study-with-bgb324-bergenbios-selective-first-in-class-axl-inhibitor-featured-at-the-2017-american-society-of-hematology-annual-meeting/ 2017-11-01T13:05:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-third-quarter-2017-results-presentation-and-webcast/ 2017-11-10T10:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-presents-bgb324-and-keytruda-pembrolizumab-clinical-trial-at-the-2017-san-antonio-breast-cancer-symposium/ 2017-11-14T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-at-jefferies-2017-london-healthcare-conference/ 2017-11-16T10:15:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-third-quarter-2017/ 2017-11-17T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-exercise-of-employee-share-options-and-increase-of-capital-2/ 2017-11-17T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-us-clinical-trial-update-2/ 2017-11-27T07:45:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-presents-update-on-ph-ii-clinical-trial-with-selective-axl-inhibitor-bgb324-in-relapsed-refractory-aml-patients-at-59th-ash-annual-meeting/ 2017-12-11T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-recent-highlights-from-its-clinical-trials-with-selective-axl-inhibitor-bgb324-at-dnbs-8th-annual-nordic-healthcare-conference/ 2017-12-14T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-18/ 2017-12-14T10:22:35+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-at-biotech-showcase-2018/ 2018-01-08T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-meets-first-efficacy-endpoint-in-phase-ii-trial-with-selective-axl-inhibitor-bgb324-bemcentinib-in-nsclc/ 2018-01-09T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-encouraging-i-o-clinical-data-with-selective-axl-inhibitor-bemcentinib-bgb324-supports-its-potential-as-cornerstone-of-cancer-therapy/ 2018-01-29T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-fourth-quarter-and-full-year-2017-results-presentation-and-webcast/ 2018-02-06T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-fourth-quarter-and-full-year-2017/ 2018-02-13T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/viktige-milepaeler-nadd-i-2017-flere-spennende-testresultater-ventes-i-2018/ 2018-02-13T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-exercise-of-employee-share-options-and-increase-of-capital/ 2018-02-13T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-notice-of-extraordinary-general-meeting-5/ 2018-02-16T12:50:33+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-har-fullfort-rekruttering-av-pasienter-til-forste-halvdel-av-fase-ii-forsoket-med-bemcentinib-i-kombinasjon-med-keytruda-i-brystkreft/ 2018-02-19T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-completes-recruitment-into-first-stage-of-phase-ii-breast-cancer-trial-with-selective-axl-inhibitor-bemcentinib-combined-with-keytruda/ 2018-02-19T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-us-clinical-trial-update/ 2018-03-15T06:55:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-lovende-data-som-viser-bemcentinibs-potensiale-til-a-forbedre-effekten-av-sjekkpunkthemmere-presenteres-pa-aacrs-arsmote/ 2018-03-15T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-promising-data-highlighting-bemcentinibs-potential-to-improve-efficacy-of-checkpoint-inhibitors-to-be-presented-at-aacr-annual-meeting/ 2018-03-15T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-overview-of-phase-ii-clinical-trial-portfolio-combining-bemcentinib-with-keytruda-at-3rd-annual-immuno-oncology-summit-europe/ 2018-03-22T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-completes-recruitment-into-first-stage-of-phase-ii-nsclc-trial-with-selective-axl-inhibitor-bemcentinib-combined-with-keytruda/ 2018-04-10T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-announces-successful-nok-187-5-million-usd-24-million-private-placement-of-new-shares/ 2018-04-13T05:15:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/promising-pre-clinical-data-supporting-bergenbios-pipeline-to-be-published-and-presented-at-upcoming-leading-conferences/ 2018-04-13T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-lovende-data-som-viser-selektiv-axl-inhibitor-bemcentinibs-potensiale-til-a-forbedre-effekten-av-sjekkpunkthemmere-ble-presentert-pa-aacr/ 2018-04-18T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-promising-data-highlighting-selective-axl-inhibitor-bemcentinibs-potential-to-improve-efficacy-of-checkpoint-inhibitors-presented-at-aacr/ 2018-04-18T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-first-quarter-2018-results-presentation-and-webcast/ 2018-05-08T14:01:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-annual-general-meeting-2/ 2018-05-14T10:25:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-participation-at-upcoming-healthcare-investor-and-life-sciences-industry-conferences/ 2018-05-14T10:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-first-quarter-2018/ 2018-05-15T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-interim-clinical-and-biomarker-data-from-phase-ii-development-programme-with-selective-axl-inhibitor-bemcentinib-at-asco/ 2018-05-16T21:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-interim-clinical-and-biomarker-data-with-selective-axl-inhibitor-bemcentinib-in-aml-and-mds-at-eha/ 2018-05-18T08:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-invitation-to-conference-call-interim-update-on-ph-ii-clinical-programme-with-selective-axl-inhibitor-bemcentinib-being-presented-at-asco/ 2018-05-29T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-provides-interim-update-on-phase-ii-clinical-programme-with-selective-oral-axl-inhibitor-bemcentinib/ 2018-06-03T14:45:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-posters-presented-at-congress-of-european-hematology-association-eha/ 2018-06-18T07:45:38+00:00 https://oncoinvent.dev2.superwp.no/press-release/selective-axl-inhibitor-bemcentinib-meets-pre-specified-efficacy-endpoint-in-stage-1-of-nsclc-phase-ii-combination-trial-with-keytruda/ 2018-06-26T06:15:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-second-quarter-and-first-half-2018-results-presentation-and-webcast/ 2018-08-14T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-second-quarter-and-first-half-2018/ 2018-08-21T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-at-the-20th-annual-global-investment-conference-in-new-york-city-september-4-6-2018/ 2018-08-30T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-interim-phase-2-clinical-data-with-selective-axl-inhibitor-bemcentinib-in-non-small-cell-lung-cancer-at-wclc/ 2018-09-05T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-updated-phii-clinical-data-with-selective-axl-inhibitor-bemcentinib-strengthens-its-potential-to-improve-nsclc-patient-outcomes/ 2018-09-25T14:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-enters-second-stage-of-phase-ii-trial-with-selective-axl-inhibitor-bemcentinib-in-combination-with-keytruda-in-patients-with-advanced-nsclc/ 2018-10-05T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-interim-phase-ii-clinical-preclinical-and-biomarker-data-with-selective-axl-inhibitor-bemcentinib-at-esmo/ 2018-10-09T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-announces-interim-biomarker-and-phase-ii-clinical-data-with-selective-axl-inhibitor-bemcentinib-presented-at-esmo/ 2018-10-22T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-late-breaking-abstract-on-phase-ii-trial-of-bemcentinib-in-combination-with-keytruda-in-advanced-nsclc-at-sitc/ 2018-11-02T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-third-quarter-2018-results-presentation-and-webcast/ 2018-11-06T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-reports-80-improvement-in-pfs-of-axl-positive-vs-axl-negative-nsclc-patients-in-bemcentinib-keytruda-phii-combination-trial/ 2018-11-06T13:15:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-third-quarter-2018/ 2018-11-13T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-appoints-cancer-drug-development-specialist-alan-barge-md-as-interim-chief-medical-officer/ 2018-11-21T14:02:25+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-reports-43-response-rate-with-bemcentinib-monotherapy-in-axl-positive-r-r-aml-mds-patients-at-ash/ 2018-12-03T02:15:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-presents-key-results-from-phii-programme-with-selective-axl-inhibitor-bemcentinib-at-dnbs-9th-annual-nordic-healthcare-conference/ 2018-12-12T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-announces-start-of-phase-ii-investigator-initiated-trial-evaluating-selective-axl-inhibitor-bemcentinib-in-high-risk-mds/ 2019-01-04T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-to-present-company-overview-at-biotech-showcase-2019-during-annual-j-p-morgan-conference-in-san-francisco/ 2019-01-08T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-announces-start-of-phase-i-trial-evaluating-first-in-class-anti-axl-antibody-bgb149/ 2019-01-09T11:18:22+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-announces-start-of-phase-i-trial-evaluating-adct-601-a-novel-anti-axl-adc-in-patients-with-advanced-solid-tumours/ 2019-01-21T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-fourth-quarter-and-full-year-2018-results-presentation-and-webcast/ 2019-02-05T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-fourth-quarter-and-full-year-2018/ 2019-02-12T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-publishes-annual-report-for-2018/ 2019-02-20T15:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-or-the-company-announces-key-appointments-to-executive-team-and-board-to-prepare-organisation-for-next-phase-of-development/ 2019-03-13T23:58:43+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-bemcentinib-in-combination-with-low-dose-chemotherapy-achieves-efficacy-endpoint-in-aml-patients/ 2019-04-01T10:01:12+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-preclinical-data-presented-at-aacr-reinforces-bemcentinibs-potential-to-reverse-tumour-immunosuppression-and-therapy-resistance/ 2019-04-02T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-extends-phase-ii-trial-with-bemcentinib-and-keytruda-in-nsclc-to-include-patients-with-disease-progression-on-immune-checkpoint-inhibitor-therapy/ 2019-04-02T08:53:22+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-h-c-wainwright-global-life-sciences-conference/ 2019-04-09T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-17/ 2019-04-15T11:53:33+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-nsclc-and-aml-clinical-data-from-phase-ii-development-programme-with-selective-axl-inhibitor-bemcentinib-at-asco-2019/ 2019-04-23T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-first-quarter-presentation-and-webcast/ 2019-04-24T09:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-first-quarter-2019/ 2019-05-08T05:01:55+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-completes-recruitment-into-second-stage-of-phase-ii-trial-with-selective-axl-inhibitor-bemcentinib-in-combination-with-keytruda-in-patients-with-advanced-nsclc/ 2019-05-08T10:15:18+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-new-nsclc-and-aml-clinical-data-and-biomarker-data-from-phase-ii-development-programme-with-selective-axl-inhibitor-bemcentinib-at-asco-2019/ 2019-05-15T21:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-asco-update-call/ 2019-05-31T12:07:24+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-new-preliminary-clinical-and-biomarker-data-showing-durable-response-median-survival-rates-in-phase-ii-trial-with-bemcentinib-and-keytruda-in-pts-with-advanced-nscl/ 2019-06-02T13:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-new-phase-ii-clinical-data-that-bemcentinib-in-combination-with-low-dose-chemotherapy-improves-efficacy-and-duration-of-survival-in-elderly-aml-patients-at-asco-2019/ 2019-06-03T13:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-contemplated-private-placement-2/ 2019-06-13T14:40:10+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-successfully-completed-private-placement/ 2019-06-13T22:03:03+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-preliminary-phase-ii-clinical-data-at-eha-24-bemcentinib-in-combination-with-low-dose-chemotherapy-yields-durable-responses-in-aml-patients-unfit-for-intensive-chemo/ 2019-06-14T10:00:52+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-primary-insider-notification-2/ 2019-06-20T14:47:48+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-16/ 2019-06-21T08:36:20+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-exercise-of-share-options-and-increase-of-share-capital/ 2019-06-28T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-15/ 2019-07-01T09:15:51+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-second-quarter-and-half-year-2019-results-presentation-and-webcast/ 2019-08-08T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-second-quarter-and-first-half-2019-3/ 2019-08-19T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-second-quarter-and-first-half-2019-2/ 2019-08-19T07:39:44+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-second-quarter-and-first-half-2019/ 2019-08-19T08:06:28+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-increase-of-share-capital-exercise-of-share-options-and-primary-insider-notification/ 2019-08-28T14:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-primary-insider-notification/ 2019-09-02T15:00:50+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-14/ 2019-09-03T09:00:49+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-phase-ii-trial-updates-with-selective-axl-inhibitor-bemcentinib-in-non-small-cell-lung-cancer-at-2019-world-conference-on-lung-cancer/ 2019-09-08T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-h-c-wainwright-21st-annual-global-life-sciences-conference/ 2019-09-10T11:13:23+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-phase-ii-trial-updates-with-selective-axl-inhibitor-bemcentinib-at-the-european-society-for-medical-oncology-esmo-2019-congress/ 2019-09-27T10:04:51+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-clinical-data-from-phase-ii-trial-with-selective-axl-inhibitor-at-34th-annual-sitc-meeting/ 2019-10-02T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-receives-fda-approval-of-fast-track-designation-for-bemcentinib/ 2019-10-22T12:23:20+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbios-bemcentinib-meets-primary-endpoint-in-first-cohort-of-phase-2-nsclc-study-in-combination-with-keytruda/ 2019-11-06T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-third-quarter-2019-results-presentation-and-webcast/ 2019-11-07T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-clinical-data-from-phase-ii-combination-trial-of-bemcentinib-and-ldac-trial-in-elderly-aml-patients-at-ash-2019/ 2019-11-07T11:33:26+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-updated-phase-2-nsclc-clinical-and-translational-data-for-bemcentinib-in-combination-with-keytruda/ 2019-11-08T12:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-for-the-third-quarter-2019/ 2019-11-19T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-preliminary-clinical-data-from-phase-ii-combination-trial-of-bemcentinib-and-ldac-in-elderly-aml-patients-at-ash-2019/ 2019-12-09T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-meets-efficacy-endpoint-for-first-stage-of-phase-ii-trial-with-axl-inhibitor-bemcentinib-in-combination-with-keytruda-in-nsclc-patients-progressing-on-immune-chec/ 2020-01-15T16:10:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-contemplated-private-placement/ 2020-01-29T15:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-private-placement-successfully-placed-2/ 2020-01-29T23:27:06+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-key-information-related-to-the-subsequent-offering-2/ 2020-01-29T23:39:02+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bgbio-notice-of-extraordinary-general-meeting/ 2020-01-30T07:04:16+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-fourth-quarter-and-full-year-2019-results-presentation-and-webcast/ 2020-02-03T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-13/ 2020-02-05T09:21:48+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-results-for-the-fourth-quarter-and-full-year-2019/ 2020-02-11T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-resolution-to-carry-out-a-share-capital-increase-in-connection-with-the-private-placement-and-the-subsequent-offering/ 2020-02-20T17:21:24+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-osebgbio-annual-report-2019/ 2020-02-24T16:30:40+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-ose-bgbio-notice-of-annual-general-meeting/ 2020-02-24T16:42:16+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-approval-of-prospectus-2/ 2020-02-26T14:51:43+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-commencement-of-the-subsequent-offering-2/ 2020-02-26T15:00:37+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-12/ 2020-03-02T14:19:22+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-last-day-of-subscription-period-in-the-subsequent-offering-2/ 2020-03-12T10:52:51+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-of-the-subsequent-offering-2/ 2020-03-12T22:24:03+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-final-results-of-the-subsequent-offering-2/ 2020-03-13T15:37:46+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-annual-general-meeting/ 2020-03-16T17:49:02+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-provides-covid-19-impact-assessment/ 2020-03-27T15:41:04+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-the-upcoming-2020-solebury-trout-virtual-investor-conference/ 2020-03-30T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-11/ 2020-03-30T11:55:44+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-option-grant/ 2020-04-14T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative-2/ 2020-04-28T21:41:49+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbios-bemcentinib-selected-to-be-fast-tracked-as-potential-treatment-for-covid-19-through-new-national-uk-government-clinical-trial-initiative/ 2020-04-29T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-contemplated-private-placement/ 2020-05-04T14:33:58+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-updated-corporated-presentation/ 2020-05-04T15:14:58+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-private-placement-successfully-placed/ 2020-05-04T21:50:49+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-key-information-related-to-the-subsequent-offering/ 2020-05-05T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-raises-nok500m-e45-4m-via-an-over-subscribed-private-placement/ 2020-05-05T05:05:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-10/ 2020-05-11T07:32:15+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-first-quarter-2020-results-webcast-presentation/ 2020-05-13T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-results-for-the-first-quarter-2020/ 2020-05-19T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-notice-of-extraordinary-general-meeting-4/ 2020-05-29T10:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-confirms-first-covid19-patient-dosed-with-bemcentinib-in-accord-trial/ 2020-06-02T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-abg-sundal-collier-oncology-seminar/ 2020-06-09T12:01:32+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-top-line-translational-phase-ii-data-with-bemcentinib-in-combination-with-keytruda-in-nsclc-patients-at-next-gen-immuno-oncology-congress/ 2020-06-15T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-resolution-to-carry-out-a-share-capital-increase-in-connection-with-the-subsequent-offering/ 2020-06-19T14:35:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-approval-of-prospectus/ 2020-06-19T14:37:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-commencement-of-the-subsequent-offering/ 2020-06-19T14:38:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-the-upcoming-virtual-european-biotech-investor-day-2020/ 2020-06-23T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-change-to-presentation-time-at-next-gen-immuno-oncology-congress/ 2020-06-24T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-positive-interim-clinical-and-translational-data-from-phase-ii-trial-of-bemcentinib-in-combination-with-keytruda-in-checkpoint-inhibitor-refractory-nsclc-pat/ 2020-06-25T17:05:06+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-last-day-of-subscription-period-in-the-subsequent-offering/ 2020-07-03T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-results-of-the-subsequent-offering/ 2020-07-03T18:57:37+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-final-results-of-the-subsequent-offering/ 2020-07-06T14:35:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-digital-novel-coronavirus-investment-forum/ 2020-07-07T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-amendment-to-the-accord-clinical-trial-protocol-for-bemcentinib-as-potential-treatment-for-covid-19/ 2020-07-08T15:03:14+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-registered-share-capital-increase/ 2020-07-16T08:10:20+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-first-patient-dosed-in-recurrent-glioblastoma-investigator-sponsored-phase-i-ii-study-assessing-selective-axl-inhibitor-bemcentinib/ 2020-07-20T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-update-on-bemcentinibs-involvement-in-potential-treatment-of-covid-19-pandemic/ 2020-07-28T15:35:08+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-second-quarter-2020-results-webcast-presentation/ 2020-08-10T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbios-bemcentinib-meets-efficacy-endpoint-in-bergamo-phase-ii-trial-with-high-risk-myelodysplastic-syndromes-or-acute-myeloid-leukemia/ 2020-08-18T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbios-bemcentinib-oppfyller-effektendepunktet-i-bergamo-fase-ii-forsok-hos-pasienter-med-hoyrisiko-myelodysplastiske-syndromer-eller-akutt-myeloide-leukemi/ 2020-08-18T05:01:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-results-for-the-second-quarter-and-first-half-of-2020/ 2020-08-18T05:02:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-upcoming-investor-conferences-2/ 2020-09-01T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-receives-approval-to-commence-phase-ii-trial-of-bemcentinib-for-covid-19-in-south-africa/ 2020-09-11T13:25:17+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-far-godkjenning-til-a-starte-fase-ii-forsok-av-bemcentinib-for-covid-19-i-sor-afrika/ 2020-09-11T13:25:35+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-sachs-annual-biotech-in-europe-forum/ 2020-09-18T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-receives-approval-from-norwegian-regional-ethics-committee-for-covid-19-south-africa-trial/ 2020-09-24T18:25:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-far-godkjenning-fra-rek-regional-etisk-komite-for-covid-19-forsok-i-sor-afrika/ 2020-09-24T18:26:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-accord-clinical-study-assessing-bemcentinib-in-covid-19-patients-to-recommence-in-uk/ 2020-09-28T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-accord-klinisk-studie-av-bemcentinib-for-covid-19-pasienter-gjenopptas-i-storbritannia/ 2020-09-28T05:01:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-receives-regulatory-approval-to-commence-phase-ii-trial-of-bemcentinib-for-covid-19-in-india/ 2020-09-30T19:46:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-far-regulatorisk-godkjenning-til-a-starte-fase-ii-forsok-av-bemcentinib-for-covid-19-i-india/ 2020-09-30T19:47:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-first-patient-dosed-with-bemcentinib-in-relapsed-malignant-pleural-mesothelioma-investigator-sponsored-phase-iia-study/ 2020-10-07T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-kunngjor-forste-pasient-dosert-med-bemcentinib-i-tilbakevendende-malignt-pleuralt-mesoteliom-lungehinnekreft-i-sponset-fase-iia-utprovingsstudie/ 2020-10-07T05:01:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-data-on-anti-axl-antibody-tilvestamab-at-32nd-ena-symposium/ 2020-10-14T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenterer-data-om-anti-axl-antistoff-tilvestamab-pa-32nd-ena-symposium/ 2020-10-14T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenterer-kliniske-translasjonsdata-fra-den-pagaende-fase-ii-kombinasjonsstudien-i-ikke-smacellet-lungekreft-nsclc-under-den-arlige-sitc-konferansen/ 2020-10-15T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-clinical-translational-data-from-the-ongoing-phase-ii-bemcentinib-combination-study-in-nsclc-at-annual-sitc-meeting/ 2020-10-15T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-bekrefter-forste-pasient-registrert-i-fase-ii-studie-av-bemcentinib-som-en-potensiell-behandling-for-covid-19-pasienter-i-sor-afrika/ 2020-10-21T09:36:29+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-confirms-first-patient-enrolled-in-phase-ii-trial-assessing-bemcentinib-as-a-potential-treatment-for-covid-19-patients-in-south-africa/ 2020-10-21T09:36:29+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-virtual-rd-day-06-november-2020/ 2020-10-23T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-third-quarter-2020-results/ 2020-11-03T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenterer-oppdaterte-kliniske-data-fra-fase-ii-kombinasjonsstudien-av-bemcentinib-og-ldac-hos-eldre-pasienter-med-tilbakevennende-aml-pa-ash-2020-konferansen/ 2020-11-04T19:45:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-updated-clinical-data-from-its-phase-ii-combination-trial-of-bemcentinib-and-ldac-in-elderly-relapsed-aml-patients-at-ash-2020-meeting/ 2020-11-04T19:45:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-hosting-virtual-rd-day-today/ 2020-11-06T09:35:52+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenterer-fase-ii-bemcentinib-kombinasjonsstudie-i-ikke-smacellet-lungekreft-nsclc-pa-den-arlige-sitc-konferansen/ 2020-11-11T13:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-phase-ii-bemcentinib-combination-study-in-nsclc-at-annual-sitc-meeting/ 2020-11-11T13:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-third-quarter-2020-results/ 2020-11-17T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-innkalling-til-ekstraordinaer-generalforsamling/ 2020-11-18T15:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-notice-of-extraordinary-general-meeting-3/ 2020-11-18T15:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-bekrefter-forste-pasient-rekruttert-i-fase-ii-studie-av-bemcentinib-som-en-potensiell-behandling-av-covid-19-pasienter-i-india/ 2020-11-24T08:50:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-confirms-first-patient-enrolled-in-phase-ii-trial-assessing-bemcentinib-as-a-potential-treatment-for-covid-19-in-india/ 2020-11-24T08:50:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-updated-clinical-data-at-ash-2020-meeting/ 2020-11-30T08:20:30+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-upcoming-healthcare-conferences-in-december-2020/ 2020-12-03T14:40:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenterer-oppdaterte-kliniske-data-fra-to-fase-ii-kombinasjonsstudier-av-bemcentinib-i-aml-og-mds-pasienter-pa-ash-2020-konferansen/ 2020-12-06T15:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-updated-clinical-data-from-two-phase-ii-studies-of-bemcentinib-in-aml-and-mds-patients-at-ash-2020/ 2020-12-06T15:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-bekrefter-forste-pasient-rekruttert-med-bemcentinib-i-accord-klinisk-studie/ 2020-12-08T13:35:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-confirms-first-covid-19-patient-enrolled-with-bemcentinib-in-accord-trial/ 2020-12-08T13:35:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-extraordinary-general-meeting-today/ 2020-12-09T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-extraordinary-general-meeting/ 2020-12-09T16:35:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-an-update-on-the-ongoing-phase-ii-study-of-bemcentinib-in-combination-with-pembrolizumab-in-refractory-nsclc-at-wclc-2020/ 2020-12-16T16:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-data-monitoring-committee-recommends-continuation-of-bergenbios-bgbc020-trial-assessing-bemcentinib-in-covid-19-patients/ 2021-01-11T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenting-at-virtual-investor-conferences/ 2021-01-12T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-updates-from-ongoing-phase-ii-bemcentinib-combination-study-in-refractory-nsclc-at-wclc-2020/ 2021-01-13T06:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenterer-oppdateringer-fra-den-pagaende-fase-ii-bemcentinib-kombinasjonsstudien-i-ikke-smacellet-lungekreft-nsclc-pa-wclc-2020-2/ 2021-01-13T07:19:44+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-fourth-quarter-2020-results/ 2021-01-27T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-updates-from-ongoing-phase-ii-bemcentinib-combination-study-in-refractory-nsclc-at-wclc-2020/ 2021-01-29T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenterer-oppdateringer-fra-den-pagaende-fase-ii-bemcentinib-kombinasjonsstudien-i-ikke-smacellet-lungekreft-nsclc-pa-wclc-2020/ 2021-01-29T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-second-data-monitoring-committee-recommends-continuation-of-bergenbios-bgbc020-trial-assessing-bemcentinib-in-covid-19-patients/ 2021-02-08T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-results-for-the-fourth-quarter-and-full-year-2020/ 2021-02-10T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-preclinical-covid-19-data-at-the-conference-on-retroviruses-and-opportunistic-infections-croi-2021/ 2021-02-17T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-board-approval-of-2020-annual-financial-statement/ 2021-02-23T20:35:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-annual-report-2020/ 2021-02-25T14:35:47+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-notice-of-annual-general-meeting-3/ 2021-02-25T15:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-increase-of-share-capital-exercise-of-share-options-8/ 2021-03-02T16:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-closes-recruitment-into-trial-assessing-bemcentinib-in-covid-19-patients/ 2021-03-04T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-9/ 2021-03-04T08:27:32+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-start-of-phase-1b-trial-of-anti-axl-antibody-tilvestamab-bgb149/ 2021-03-05T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-preclinical-covid-19-data-at-annual-conference-on-retroviruses-and-opportunistic-infections-croi-2021-2/ 2021-03-06T08:27:38+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-preclinical-covid-19-data-at-annual-conference-on-retroviruses-and-opportunistic-infections-croi-2021/ 2021-03-06T10:13:39+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-upcoming-investor-conferences/ 2021-03-08T09:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-completes-enrolment-into-latest-cohort-of-phase-ii-bemcentinib-combination-study-in-refractory-nsclc/ 2021-03-12T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-disclosure-of-large-shareholdings-proxies-received-in-connection-with-the-agm-19th-march-2021/ 2021-03-15T15:40:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-minutes-from-the-annual-general-meeting/ 2021-03-19T17:13:09+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-stopped-recruitment-to-the-bemcentinib-arm-in-uk-accord-covid-platform-trial/ 2021-03-30T20:03:50+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-update-from-investigational-phase-ii-trials-assessing-bemcentinib-in-hospitalised-covid-19-patients/ 2021-04-19T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-kunngjor-oppdatering-fra-fase-ii-utprovingsstudier-av-bemcentinib-i-sykehusinnlagte-covid-19-pasienter/ 2021-04-19T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenting-at-arctic-securities-biotech-webinar/ 2021-04-21T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-increase-of-share-capital-exercise-of-share-options-7/ 2021-04-23T15:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bemcentinib-pre-clinical-covid-19-data-to-be-presented-at-virutal-immunology-2021/ 2021-04-26T13:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-the-american-society-of-clinical-oncology-asco-annual-meeting/ 2021-04-28T15:06:30+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-8/ 2021-04-30T09:06:08+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-presentation-of-first-quarter-2021-results/ 2021-05-05T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-grant-of-share-options-4/ 2021-05-07T17:15:50+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bemcentinib-pre-clinical-covid-19-data-presented-at-virtual-immunology-2021/ 2021-05-11T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-updated-clinical-data-at-european-hematology-association-eha-2021-virtual-meeting/ 2021-05-12T14:03:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-kunngjor-topplinjedata-fra-fase-ii-utprovingsstudie-av-bemcentinib-i-sykehusinnlagte-covid-19-pasienter/ 2021-05-18T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-top-line-data-from-phase-ii-trial-assessing-bemcentinib-in-hospitalised-covid-19-patients/ 2021-05-18T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenting-at-sachs-7th-annual-immuno-oncology-innovation-forum/ 2021-05-18T12:41:42+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-results-for-the-first-quarter-2021/ 2021-05-19T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-data-from-phase-i-ii-bemcentinib-erlotinib-combination-trial-in-nsclc-at-asco-meeting/ 2021-05-20T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-abgsc-seminar/ 2021-05-25T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-data-from-phase-i-ii-bemcentinib-erlotinib-combination-trial-in-nsclc-at-asco-meeting/ 2021-06-04T13:42:30+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-preclinical-data-on-tilvestamab-in-chronic-kidney-disease-at-era-edta-virtual-congress-2021/ 2021-06-07T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-mottar-fda-fast-track-designation-for-bemcentinib-anti-pd-l1-kombinasjon-i-nsclc/ 2021-06-08T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-receives-fda-fast-track-designation-for-bemcentinib-anti-pd-l1-combination-in-nsclc/ 2021-06-08T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-late-breaking-abstract-presentation-at-eccmid-2021/ 2021-06-10T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenterer-lovende-oppdaterte-preliminaere-data-fra-fase-ii-studie-i-aml-pasienter-med-tilbakefall-pa-virtuelt-eha-seminar/ 2021-06-11T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-encouraging-updated-preliminary-data-from-phase-ii-study-in-relapsed-aml-patients-at-eha-virtual-meeting/ 2021-06-11T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-increase-of-share-capital-exercise-of-share-options-and-disclosure-of-trade-by-primary-insider/ 2021-06-11T18:24:15+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-7/ 2021-06-16T10:41:43+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-4th-annual-next-gen-immuno-oncology-virtual-congress/ 2021-06-28T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presenting-covid-19-data-in-late-breaking-abstract-presentation-at-eccmid-2021/ 2021-06-29T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-preclinical-bemcentinib-and-tilvestamab-data-presented-at-eau-2021/ 2021-07-10T11:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-encouraging-combined-data-for-bemcentinib-from-two-phase-ii-covid-19-studies-at-eccmid/ 2021-07-12T12:12:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-covid-19-data-presented-at-the-annual-american-society-for-virology/ 2021-07-21T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-presentation-of-second-quarter-and-half-year-2021-results/ 2021-08-04T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-changes-to-senior-management/ 2021-08-06T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-results-for-the-second-quarter-and-first-half-of-2021/ 2021-08-17T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-leadership-change/ 2021-08-22T18:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-lederskifte/ 2021-08-22T18:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-increase-of-share-capital-exercise-of-share-options-6/ 2021-08-23T16:42:22+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-6/ 2021-08-26T15:25:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-increase-of-share-capital-exercise-of-share-options-5/ 2021-08-31T15:55:45+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-5/ 2021-09-06T07:35:59+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-completes-recruitment-of-phase-ii-aml-study-bgbc003/ 2021-09-07T17:21:23+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-increase-of-share-capital-exercise-of-share-options-4/ 2021-09-30T15:05:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-poster-presentation-at-society-for-immunotherapy-of-cancer-sitc-annual-meeting-2021/ 2021-10-01T13:19:50+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-4/ 2021-10-04T08:24:37+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-third-quarter-2021-results-presentation-and-webcast/ 2021-11-04T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-updated-bemcentinib-aml-data-at-ash-2021-meeting/ 2021-11-04T14:11:36+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-pre-clinical-and-clinical-data-on-bemcentinib-in-stk11-positive-nsclc-at-sitc-annual-meeting-2021/ 2021-11-09T13:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-receives-fda-fast-track-designation-for-bemcentinib-in-stk11-mutated-advanced-metastatic-non-small-lung-cancer-nsclc/ 2021-11-09T13:05:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-increase-of-share-capital-exercise-of-share-options-3/ 2021-11-09T15:29:24+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-results-for-the-third-quarter-of-2021/ 2021-11-16T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-3/ 2021-11-17T16:50:59+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-updated-bemcentinib-aml-data-at-ash-2021-meeting/ 2021-12-13T14:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-dnb-nordic-healthcare-conference-2021/ 2021-12-14T06:42:56+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-exclusive-in-license-of-key-intellectual-property-rights-from-ut-southwestern-medical-center/ 2021-12-16T06:30:22+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-notice-of-extraordinary-general-meeting-2/ 2021-12-16T14:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-mandatory-notification-of-trade-by-primary-insiders-2/ 2022-01-06T07:58:17+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-extraordinary-general-meeting-held/ 2022-01-06T09:27:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-appoints-anders-tullgren-as-chairman-of-board/ 2022-01-06T09:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-mandatory-notification-of-trade-by-primary-insider-3/ 2022-01-07T08:03:57+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-mandatory-notification-of-trade-by-primary-insiders/ 2022-01-07T16:51:04+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-mandatory-notification-of-trade-by-primary-insider-2/ 2022-01-10T18:52:51+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-and-oslo-university-hospital-announce-the-axl-inhibitor-bemcentinib-will-be-studied-in-the-eu-funded-eu-solidact-trial-in-hospitalised-covid-19-patients/ 2022-01-27T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-increase-of-share-capital-exercise-of-share-options-2/ 2022-01-27T19:55:53+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-2/ 2022-02-03T13:07:04+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-fourth-quarter-2021-results-webcast/ 2022-02-08T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-results-for-the-fourth-quarter-and-full-year-2021/ 2022-02-16T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-increase-of-share-capital-exercise-of-share-options/ 2022-02-16T16:10:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase/ 2022-02-22T11:00:30+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-publication-in-cell-reports-medicine-journal-indicating-efficacy-of-bemcentinib-in-stk11-lkb1-lung-cancer-population-2/ 2022-03-17T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-carnegie-virtual-nordic-healthcare-seminar/ 2022-03-17T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-publication-in-cell-reports-medicine-journal-indicating-efficacy-of-bemcentinib-in-stk11-lkb1-lung-cancer-population/ 2022-03-17T07:15:01+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-board-approval-of-2021-annual-financial-statement-and-annual-report-2021/ 2022-04-07T12:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-notice-of-annual-general-meeting-2/ 2022-04-07T13:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-strengthens-its-leadership-team-with-appointment-of-cristina-oliva-as-chief-medical-officer/ 2022-04-11T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-bemcentinib-covid-19-clinical-trial-data-at-eccmid-2022/ 2022-04-25T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-complete-data-analysis-of-accord2-phase-ii-bemcentinib-study-in-hospitalized-covid-19-patients-primary-efficacy-endpoint-met/ 2022-04-26T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-arctic-securities-biotech-webinar/ 2022-04-26T08:51:44+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-minutes-from-the-annual-general-meeting/ 2022-04-28T09:28:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-launch-of-business-strategy-focused-on-nsclc-and-covid-19/ 2022-05-04T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-abg-sundal-collier-life-science-summit/ 2022-05-16T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-first-quarter-2022-results-webcast/ 2022-05-18T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-results-for-the-first-quarter-2022/ 2022-05-24T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-clinical-data-on-bemcentinib-in-combination-with-docetaxel-in-patients-with-previously-treated-advanced-nsclc-at-asco-annual-meeting-2022/ 2022-06-06T16:18:49+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-mandatory-notification-of-trade-by-primary-insider/ 2022-06-16T10:58:22+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-invitation-to-second-quarter-and-half-year-2022-results-webcast/ 2022-08-09T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-reports-second-quarter-and-half-year-2022-financial-results-and-provides-business-update/ 2022-08-23T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-pareto-securities-13th-annual-healthcare-conference/ 2022-09-07T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-annouces-first-patient-randomized-in-bemcentinib-trial-in-eu-solidact-platform-for-hospitalized-covid-19-patients/ 2022-09-27T13:02:30+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-initiation-of-phase-1b-2a-trial-evaluating-bemcentinib-in-1st-line-non-small-cell-lung-cancer-patients-harboring-stk11-mutations/ 2022-10-11T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-secures-nok-100-million-shareholder-loan-facility-from-meteva-as/ 2022-10-25T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-third-quarter-2022-results-webcast/ 2022-11-08T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-reports-third-quarter-2022-financial-results-and-provides-business-update/ 2022-11-15T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-grant-of-share-options-3/ 2022-11-21T20:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-dnbs-nordic-healthcare-conference/ 2022-12-08T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-fourth-quarter-2022-results-webcast/ 2023-02-01T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-the-establishment-of-oncology-scientific-advisory-board/ 2023-02-02T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-positive-data-from-phase-2-trial-of-bemcentinib-in-combination-with-pembrolizumab-in-2l-nsclc-patients/ 2023-02-15T16:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-reports-fourth-quarter-2022-financial-results-and-provides-business-update/ 2023-02-16T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-first-patient-dosed-in-phase-1b-2a-trial-evaluating-bemcentinib-in-1st-line-non-small-cell-lung-cancer-with-stk11-mutations/ 2023-03-09T10:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-the-carnegie-nordic-healthcare-conference/ 2023-03-16T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-upcoming-scientific-conferences/ 2023-03-28T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-presents-data-on-stk11-loss-of-function-and-axl-activation-at-aacr/ 2023-04-18T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-foreslar-delvis-garantert-fortrinnsrettsemisjon/ 2023-04-25T15:48:03+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-proposed-partially-underwritten-rights-issue/ 2023-04-25T15:48:03+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-key-information-relating-to-the-preferential-rights-issue/ 2023-04-25T15:56:39+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-board-approval-of-2022-annual-financial-statement-and-annual-report-2022/ 2023-04-28T10:59:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-notice-of-annual-general-meeting/ 2023-04-28T13:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-hold-business-update-conference-call/ 2023-05-09T16:14:05+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-terms-of-the-partially-underwritten-rights-issue/ 2023-05-20T10:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-updated-key-information-relating-to-the-preferential-rights-issue/ 2023-05-20T10:05:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-annual-general-meeting-held/ 2023-05-22T16:01:45+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bgbio-ex-subscription-rights-today/ 2023-05-23T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-mandatory-notification-of-trade-by-related-party-to-primary-insiders-2/ 2023-05-24T18:11:49+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-abstracts-accepted-for-presentation-at-2023-asco/ 2023-05-25T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-approval-and-publication-of-prospectus-for-the-preferential-rights-issue/ 2023-05-26T12:41:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-commencement-of-the-subscription-period-for-the-rights-issue/ 2023-05-30T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-receipt-of-subscription-rights-in-the-rights-issue-by-primary-insiders-and-their-close-associates/ 2023-05-30T11:28:17+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-participate-in-investor-webcast-and-qa/ 2023-05-30T16:19:16+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-data-from-bemcentinib-trial-in-mesothelioma-presented-at-asco/ 2023-06-05T20:11:12+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-last-day-of-trading-in-subscription-rights/ 2023-06-07T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-mandatory-notification-of-trade-by-primary-insiders-and-close-associates-5/ 2023-06-07T15:20:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-mandatory-notification-of-trade-by-primary-insiders-and-close-associates-4/ 2023-06-08T20:01:16+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-last-day-of-the-subscription-period-in-the-rights-issue/ 2023-06-13T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-mandatory-notification-of-trade-by-primary-insiders-and-close-associates-3/ 2023-06-13T07:49:04+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-preliminary-results-indicates-an-oversubscribed-rights-issue-of-gross-nok-250-million/ 2023-06-13T18:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-final-results-of-the-rights-issue/ 2023-06-14T11:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-correction-of-final-results-of-the-rights-issue/ 2023-06-14T13:20:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-mandatory-notification-of-trade-allocations-to-primary-insiders-and-close-associates-in-the-rights-issue/ 2023-06-15T06:10:40+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-updated-timeline-for-delivery-of-offer-shares-and-warrants-in-connection-with-the-rights-issue/ 2023-06-19T14:40:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-reports-first-quarter-2023-financial-results-and-provides-business-update/ 2023-06-22T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-new-share-capital-and-warrants-registered/ 2023-06-22T09:36:50+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-correction-new-share-capital-and-warrants-registered/ 2023-06-22T10:36:27+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-information-about-the-warrants-issued-in-connection-with-the-rights-issue/ 2023-06-23T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-resolution-to-increase-the-share-capital-for-settlement-of-underwriting-commission-2/ 2023-06-27T11:10:19+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-share-capital-increase-registered/ 2023-06-29T12:39:09+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-second-quarter-and-half-year-2023-results-webcast/ 2023-08-16T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-clinical-data-presentations-highlighting-the-activity-of-its-selective-axl-inhibitor-bemcentinib-in-non-small-cell-lung-cancer/ 2023-08-22T08:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-reports-second-quarter-2023-financial-results/ 2023-08-23T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/correction-bergenbio-asa-seccond-quarter-and-half-year-2023-financial-report/ 2023-08-27T18:35:14+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-company-update-at-h-c-wainright-annual-global-investment-conference-2/ 2023-09-11T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-additional-data-on-bergenbios-selective-axl-inhibitor-bemcentinib-to-be-presented-at-the-2023-esmo-meeting/ 2023-10-16T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-new-data-on-bergenbios-selective-axl-inhibitor-bemcentinib-released-today-at-2023-esmo-meeting/ 2023-10-23T05:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-poster-presentation-at-upcoming-sitc-meeting/ 2023-10-31T13:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-poster-presentation-at-upcoming-ash-meeting/ 2023-11-02T13:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-data-from-biomarker-analyses-in-2l-nsclc/ 2023-11-06T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-third-quarter-2023-results-webcast/ 2023-11-06T11:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-reports-third-quarter-2023-financial-results/ 2023-11-14T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-start-av-den-forste-utovelsesperioden-for-de-frittstaende-tegningsrettene-utstedt-i-forbindelse-med-fortrinnsrettsemisjonen/ 2023-11-15T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-commencement-of-the-first-exercise-period-for-warrants-issued-in-connection-with-rights-issue/ 2023-11-15T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-mandatory-notification-of-trade-by-primary-insiders-and-close-associates-2/ 2023-11-21T14:23:28+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-information-about-the-first-exercise-period-for-warrants-issued-in-connection-with-rights-issue/ 2023-11-24T12:46:15+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-siste-dag-av-den-forste-utovelsesperioden-for-de-frittstaende-tegningsrettene-utstedt-i-forbindelse-med-fortrinnsrettsemisjonen/ 2023-11-28T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-last-day-of-the-first-exercise-period-for-warrants-issued-in-connection-with-rights-issue/ 2023-11-28T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-preliminary-results-for-the-first-exercise-period-for-warrants-issued-in-connection-with-rights-issue/ 2023-11-29T18:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-final-results-for-the-first-exercise-period-for-warrants-issued-in-connection-with-rights-issue/ 2023-11-30T16:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-updated-timeline-for-delivery-of-new-shares/ 2023-12-07T09:47:35+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-approval-and-publication-of-prospectus-2/ 2023-12-07T13:05:40+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-new-share-capital-registered-3/ 2023-12-08T07:32:54+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-grant-of-share-options-2/ 2023-12-08T17:10:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-final-bemcentinib-phase-2-data-in-aml-and-mds-presented-at-the-2023-ash-meeting/ 2023-12-11T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-at-dnb-nordic-healthcare-conference/ 2023-12-12T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-closure-of-eu-solidact-bemcentinib-study-arm-in-hospitalized-covid-19-patients/ 2023-12-15T15:48:06+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-fourth-quarter-2023-results-webcast/ 2024-02-06T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-new-preclinical-data-indicating-broadened-potential-for-bemcentinib-to-treat-severe-respiratory-infections/ 2024-02-07T11:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbios-fourth-quarter-2023-results-focused-strategy-gathers-momentum/ 2024-02-14T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbios-resultater-for-fjerde-kvartal-2023-fokusert-strategi-gir-momentum/ 2024-02-14T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-approval-and-publication-of-a-prospectus-supplement/ 2024-02-19T16:58:47+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-participate-in-carnegie-nordic-healthcare-seminar/ 2024-03-04T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-initiation-of-phase-2a-in-first-line-non-small-lung-cancer-patients-with-a-stk11-mutation/ 2024-03-20T16:15:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-exercise-price-in-the-last-exercise-period-for-warrants-issued-in-connection-with-rights-issue/ 2024-03-27T14:59:34+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-secures-underwriting-of-nok-118-million-gross-proceeds-representing-minimum-80-exercise-of-the-remaining-warrants-providing-funding-into-2h-2025/ 2024-04-02T05:55:06+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-start-av-den-siste-utovelsesperioden-for-de-frittstaende-tegningsrettene-utstedt-i-forbindelse-med-fortrinnsrettsemisjonen/ 2024-04-02T06:50:21+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-commencement-of-the-last-exercise-period-for-warrants-issued-in-connection-with-rights-issue/ 2024-04-02T06:50:21+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-information-about-the-last-exercise-period-for-warrants-issued-in-connection-with-rights-issue/ 2024-04-03T11:22:38+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-mandatory-notification-of-trade-by-related-party-to-primary-insiders/ 2024-04-08T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-last-day-of-trading-in-warrants/ 2024-04-08T05:15:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-siste-dag-av-den-siste-utovelsesperioden-for-de-frittstaende-tegningsrettene-utstedt-i-forbindelse-med-fortrinnsrettsemisjonen/ 2024-04-15T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-last-day-of-the-last-exercise-period-for-warrants-issued-in-connection-with-rights-issue/ 2024-04-15T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-mandatory-notification-of-trade-by-primary-insiders-and-close-associates/ 2024-04-15T08:58:31+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-final-results-for-the-last-exercise-period-for-warrants-issued-in-connection-with-rights-issue/ 2024-04-16T12:15:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-resolution-to-increase-the-share-capital-for-settlement-of-underwriting-commission/ 2024-04-17T15:10:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-new-share-capital-registered-2/ 2024-04-25T10:55:37+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-board-approval-of-2023-annual-financial-statement-and-annual-report-2023/ 2024-04-30T11:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-notice-of-annual-general-meeting-2/ 2024-04-30T12:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-first-quarter-2024-results-webcast/ 2024-05-22T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-minutes-from-the-annual-general-meeting-2024/ 2024-05-23T15:15:28+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-new-share-capital-registered/ 2024-05-28T08:07:48+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-key-information-relating-to-the-reverse-share-split-and-change-of-isin/ 2024-05-28T12:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-nci-clinical-collaboration-with-ut-health-san-antonio-and-sobi/ 2024-05-28T13:11:36+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-first-quarter-results-2024-advancing-to-the-next-stage-of-development/ 2024-05-29T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-ex-reverse-share-split-and-change-of-isin-today/ 2024-05-30T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-registration-of-reverse-share-split/ 2024-06-03T16:02:46+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-grant-of-share-options/ 2024-06-26T15:35:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-selection-of-2nd-dose-in-phase-2a-first-line-stk11m-non-small-lung-cancer-trial/ 2024-07-29T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-second-quarter-and-half-year-2024-results-webcast/ 2024-08-13T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-registration-of-share-capital-reduction/ 2024-08-15T07:57:31+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-collaborates-with-tempus-to-potentially-accelerate-development-in-stk11m-non-small-cell-lung-cancer/ 2024-08-20T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-second-quarter-results-2024-solid-clinical-and-financial-progress/ 2024-08-21T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-company-update-at-h-c-wainright-annual-global-investment-conference/ 2024-09-09T13:24:26+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-asa-notice-of-extraordinary-general-meeting/ 2024-09-19T13:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-safety-data-from-dose-escalation-phase-1b-in-first-line-nsclc-patients/ 2024-10-07T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-minutes-from-extraordinary-general-meeting/ 2024-10-10T09:07:04+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-ceo-martin-olin-steps-down/ 2024-10-10T19:31:12+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-third-quarter-2024-results-webcast/ 2024-11-06T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-third-quarter-results-2024/ 2024-11-13T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-appoints-olav-hellebo-as-ceo/ 2024-11-20T19:30:54+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-to-present-company-update-at-dnb-nordic-healthcare-conference/ 2024-11-26T07:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-first-patient-entered-into-advanced-adenocarcinoma-lung-cancer-trial/ 2025-01-07T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-invitation-to-fourth-quarter-2024-results-webcast/ 2025-02-18T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-avslutter-1l-stk11m-nsclc-studie-og-vil-utforske-strategiske-alternativer/ 2025-02-25T18:58:28+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-discontinuation-of-1l-stk11m-nsclc-study-and-exploration-of-strategic-alternatives/ 2025-02-25T18:58:28+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-fourth-quarter-results-2024/ 2025-02-26T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-advancement-of-its-strategic-review/ 2025-03-17T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-announces-nature-communications-publication-of-bgbc003-ph2-data-in-relapsed-refractory-acute-myeloid-leukemia-patients/ 2025-03-26T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-board-approval-of-2024-annual-financial-statement-and-annual-report-2024-and-update-on-financial-calendar/ 2025-04-29T20:03:06+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-notice-of-annual-general-meeting/ 2025-06-03T13:55:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-update-on-strategic-review-process-and-status-of-activities/ 2025-06-03T17:21:50+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-minutes-from-the-annual-general-meeting-2025/ 2025-06-26T09:29:22+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-and-oncoinvent-a-rising-innovator-in-radiopharmaceutical-cancer-therapies-announce-proposed-merger-and-a-fully-underwritten-rights-issue/ 2025-06-30T20:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-announcement-of-fully-underwritten-rights-issue/ 2025-06-30T20:05:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-key-information-related-to-the-rights-issue/ 2025-06-30T20:29:56+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-notice-of-extraordinary-general-meeting/ 2025-07-03T12:53:13+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-approval-of-the-merger-plan-and-the-fully-underwritten-rights-issue/ 2025-08-04T11:40:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-updated-key-information-related-to-the-rights-issue/ 2025-08-05T14:49:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-first-half-results-2025/ 2025-08-20T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-updated-information-regarding-the-contemplated-rights-issue-and-merger/ 2025-09-17T06:55:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-updated-key-information-related-to-the-contemplated-rights-issue/ 2025-09-17T06:56:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-and-oncoinvent-key-dates-for-completion-of-merger/ 2025-10-24T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-approval-and-publication-of-prospectus/ 2025-10-28T09:42:15+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-bergenbio-and-oncoinvent-last-day-of-trading-in-the-shares-of-oncoinvent/ 2025-10-29T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/bergenbio-asa-merger-of-bergenbio-and-oncoinvent-completed/ 2025-10-29T16:35:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-oncoinvent-appoints-dr-ramzi-amri-as-new-cfo/ 2025-10-31T07:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-mandatory-notification-of-trade/ 2025-11-03T07:55:22+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-reminder-invitation-to-presentation-of-q3-2025-company-update-on-november-4th-2025/ 2025-11-03T11:55:22+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-updated-key-information-related-to-the-contemplated-rights-issue/ 2025-11-11T16:32:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-terms-of-the-underwritten-rights-issue/ 2025-11-11T17:15:53+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-ex-subscription-rights-in-rights-issue-today/ 2025-11-12T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-receipt-of-subscription-rights-in-the-rights-issue-by-primary-insiders-and-their-close-associates-2/ 2025-11-14T09:56:22+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-receipt-of-subscription-rights-in-the-rights-issue-by-primary-insiders-and-their-close-associates/ 2025-11-14T13:51:04+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-notice-of-extraordinary-general-meeting-in-connection-with-the-rights-issue/ 2025-11-14T14:45:22+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-commencement-of-the-subscription-period-for-the-rights-issue/ 2025-11-17T05:30:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-last-day-of-trading-in-subscription-rights/ 2025-11-25T05:37:05+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-notification-of-trade-primary-insider-close-associate-3/ 2025-11-27T11:59:27+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-last-day-of-the-subscription-period-in-the-rights-issue/ 2025-12-01T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-preliminary-results-of-the-rights-issue/ 2025-12-01T17:45:06+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-final-results-of-the-rights-issue/ 2025-12-02T11:21:36+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-notification-of-trade-primary-insider-close-associate-2/ 2025-12-02T14:17:05+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-minutes-from-extraordinary-general-meeting-2/ 2025-12-05T12:04:55+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-resolution-to-increase-the-share-capital-in-connection-with-settlement-of-underwriting-fee/ 2025-12-05T12:13:09+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-notification-of-trade-primary-insider-close-associate/ 2025-12-08T05:55:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-oncoinvent-announces-publication-of-phase-1-study-results-for-radspherin-in-ovarian-cancer-in-gynecologic-oncology/ 2025-12-08T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-new-share-capital-registered-2/ 2025-12-10T17:15:13+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-notice-of-extraordinary-general-meeting/ 2025-12-18T18:02:44+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-grant-of-share-options-mandatory-notification-of-trade/ 2025-12-22T17:09:55+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-minutes-from-extraordinary-general-meeting/ 2026-01-08T12:42:41+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-grant-of-share-options-to-new-cfo/ 2026-01-13T07:12:53+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-key-information-relating-to-the-reverse-share-split-and-change-of-isin/ 2026-01-14T14:49:36+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-new-share-capital-registered/ 2026-01-15T09:12:04+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-ex-reverse-share-split-and-change-of-isin-today/ 2026-01-19T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-registration-of-reverse-share-split/ 2026-01-20T09:47:41+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-four-additional-sites-open-for-recruitment-in-oncoinvents-phase-2-trial/ 2026-01-29T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-announces-webcast-presentation-of-second-half-2025-results-on-thursday-26-february-2026/ 2026-02-16T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-oncoinvent-to-present-positive-24-month-follow-up-data-from-phase-1-ovarian-cancer-study-of-radspherin-at-esgo-2026/ 2026-02-17T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-second-half-2025-results/ 2026-02-26T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-grant-of-share-options-to-the-ceo/ 2026-03-11T21:34:24+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-oncoinvent-secures-new-patent-expanding-protection-for-radspherin/ 2026-03-19T06:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-annual-report-for-2025/ 2026-04-22T14:31:07+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-invitation-to-business-update-wednesday-29-april-2026/ 2026-04-23T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-notice-of-annual-general-meeting/ 2026-04-28T10:47:59+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-oncoinvent-presents-corporate-update-in-live-webcast/ 2026-04-29T05:00:00+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-share-capital-decrease-completed/ 2026-05-05T08:26:10+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-minutes-from-annual-general-meeting/ 2026-05-20T09:15:41+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-grant-of-share-options-to-member-of-the-board-following-agm/ 2026-05-20T18:54:56+00:00 https://oncoinvent.dev2.superwp.no/press-release/oncoinvent-asa-oncoinvent-achieves-50-recruitment-milestone-in-phase-2-ovarian-cancer-study-of-radspherin/ 2026-06-18T05:00:00+00:00